Morgan Stanley Analyst Is Bullish On Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) is among the 13 Best Nanotechnology Stocks to Buy Now.

According to The Fly, on December 2, 2025, Morgan Stanley analyst Kallum Titchmarsh established a price objective of $670, up from $656. He initiated coverage of Thermo Fisher Scientific Inc. (NYSE:TMO) with an Overweight rating. According to Titchmarsh, the end markets for Life Science Tools and Diagnostics are starting to show potential, and the company sees “plenty of catalysts” in the pipeline throughout its coverage. He also stated that there is a lot to do in the area going into 2026.

However, the analyst warned that a recent industry valuation surge in the second half of 2025 has put multiples in “a fair place,” prompting Morgan Stanley to begin the group with an in-line industry outlook.

Separately, on December 2, 2025, Thermo Fisher Scientific Inc. (NYSE:TMO) reported that it expanded the size of its current bioprocessing facilities in Incheon, Korea, and Singapore, as well as opened a new Bioprocess Design Center in Hyderabad, India.

According to Daniella Cramp, Senior Vice President and President of BioProduction group at Thermo Fisher Scientific Inc. (NYSE:TMO), the development facilitates the delivery of biologics, vaccines, and cell and gene treatments more quickly, affordably, and sustainably by bringing top-notch infrastructure and expertise closer to consumers.

Thermo Fisher Scientific Inc. (NYSE:TMO) offers life science reagents, diagnostic supplies, and laboratory and scientific equipment.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None